Headache and Migraine

NeurologyLive Editor in Chief Stephen D. Silberstein, MD discusses the importance of reaching a treatment effect that makes a significant difference in patients' lives.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.

Those with an existing inventory of eletriptan hydrobromide 40 mg tablets, lots AR5407 and CD4565, should stop use and distribution, and quarantine immediately.

The director of the MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the ongoing efforts in drug development and what the ideal future may hold for migraine medicine.

The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.

The director of the division of neurology and headache medicine specialist at Cincinnati Children’s Hospital offered insights on the updated pediatric migraine guidelines recently issued by the AAN and AHS.

The American Academy of Neurology and American Headache Society have released 2 sets of guidelines regarding the acute and preventive treatment of migraine in children and teenagers, with a focus on shared decision-making, patient education, and needs for future research.

The assistant professor and neurologist at the University of California San Francisco discussed how the presence of cranial autonomic symptoms (CAS) can be a predictor of the effect of Botox on chronic migraine.

The attending neurologist at the Montefiore Headache Center and assistant professor of neurology at the Albert Einstein College of Medicine spoke about preventive treament for perimenstrual-related migraine.

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in the armamentarium, and how therapies like eptinezumab can improve patients’ belief in their physician’s ability to help.

The CEO and co-founder of Theranica discussed the migraine treatment device’s mechanism of action and its successes in reducing medication overuse headache.

The findings demonstrated that the galcanezumab group—made up of those with both chronic and episodic migraine—experienced a 4.1-day reduction in monthly migraine headache days compared to a 1.0-day reduction with placebo.

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

The program director of neurology at the Zucker School of Medicine, Northwell Health, spoke about the great advances of the new CGRP medications available for the prevention of migraine.

After its recent FDA clearance, the smartphone-controlled Nerivio Migra makes its entrance into the market in the fall. Theranica’s CEO and co-founder spoke to its clinical efficacy and advantages for patients and physicians.

On our anniversary, take a look back at some of our most popular articles and interviews across a range of neurology topics.

The use of single-pulse transcranial magnetic stimulation, while already FDA-approved for acute and preventive migraine treatment, has shown that it can be effective in reducing the need for acute headache medications in patients with migraine.

The clinical professor of neurology at Albert Einstein College of Medicine spoke to the findings of the OVERCOME study, and how recent literature has suggested that improper prescriptions and medication use in migraine have been ongoing in spite of the current recommendations.

The director of the MedStar Georgetown Headache Center discussed the barriers to patient and clinician education in migraine and the gap in available interventions for the diverse patient population.

The investigators noted that these data provide robust and promising evidence that eptinezumab is associated with a rapid preventive effect in chronic migraine that is sustained for 3 months after a single infusion.

Your patient asks if a ketogenic diet can reduce her migraines. What will you tell her?

The chief medical officer of electroCore discussed the various data which have been published on the use of noninvasive vagus nerve stimulation in different populations of patients with migraine and headache.

The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.